 Cancer Genetics, Inc. CGIX, a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. The reverse stock split is intended to increase the per share trading price of Cancer Genetics common stock to satisfy the 1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market Rule 5550a2. Cancer Genetics common stock will continue to trade on The Nasdaq Capital Market under the symbol CGIX and under a new CUSIP number, 13739U203. 